Cerebral palsy is one of the hardest cases in this evidence atlas. Parents seeking any path forward for their child are an understandably motivated audience. The marketing around HBOT for CP has been heavy for two decades.
The evidence is clear. The cleanest negative randomized trial in the HBOT literature was done in CP. Honest framing matters here more than anywhere else, because the families involved deserve straight talk.
Quick Facts
| Field | Value |
|---|---|
| FDA approval status | NOT approved for CP |
| UHMS classification | Not on the 14 approved indications list |
| Medicare coverage | NOT covered for CP |
| Insurance coverage | Out-of-pocket only at most clinics |
| Typical out-of-pocket | $6,000-$15,000 for a 40-session course |
| Evidence grade | Negative — largest sham-controlled RCT found no benefit |
The evidence
The CP evidence base has one trial that towers over the rest. It was a clean, large, sham-controlled randomized study. The finding was that HBOT did not beat sham.
The Collet and colleagues 2001 Lancet trial, PMID 11558483 enrolled 111 children with CP. The active arm received 40 sessions of HBOT at 1.75 ATA. The control arm received 40 sessions of room air at 1.3 ATA, serving as sham.
Both arms improved similarly on motor function. The HBOT arm did not differ from sham on any outcome. The trial was published in Lancet, peer-reviewed at the highest level.
The trial is methodologically clean for several reasons. Patients and families were blinded as well as a sham allows, and the sample was large enough to detect a clinically meaningful effect. The follow-up captured the relevant outcomes.
The Hardy and colleagues 2002 follow-up cognitive analysis of the Collet trial cohort tested cognitive function. The HBOT arm did not show a cognitive benefit over the room-air sham arm.
The McDonagh and colleagues 2007 systematic review, PMID 18039243 pooled the CP literature. Best evidence came from the Collet trial. HBOT at 1.75 ATA and 1.3 ATA room air led to similar 5-6% improvements in motor function, and the review concluded the gains in both arms reflect attention, not HBOT itself.
The AHRQ Evidence Report on HBOT for brain injury, CP, and stroke, 2003 covered the CP literature. The conclusion was that the evidence did not support HBOT in CP.
A 2022 PLoS ONE systematic review on HBOT effectiveness and safety in CP children updated the synthesis. The conclusion held — no clear benefit, and ear barotrauma was a documented side effect in children.
A 2023 randomized clinical trial on long-term gait and balance, PMID 36832523 tested a different angle. The trial reported some gait gains, but the design lacked a sham control. The 2001 Collet trial design remains the gold standard, and it was negative.
The American Academy of Pediatrics position does not recommend HBOT for CP. The American Academy of Neurology guidelines also do not include HBOT.
The Lacey and colleagues 2012 Annals of Neurology trial, PMID 23071074 ran a smaller follow-up RCT in 49 children with CP. The trial again found no clinical benefit on motor function over sham, consistent with the Collet 2001 finding.
The pattern is clean. The largest sham-controlled trial showed no benefit, independent systematic reviews agreed, and specialty bodies do not recommend it.
Why parents still pursue this
CP is permanent neurologic injury. Standard therapy — physical, occupational, speech, sometimes Botox or surgery — works at the margins. Parents understandably look for anything that might help their child reach more potential.
The HBOT marketing for CP is heavy. Wellness chains including Restore Hyper Wellness and a long tail of small clinics still offer CP protocols. Testimonials drive demand.
Some parents report gains after HBOT. The Collet 2001 trial showed the sham arm reported similar gains. The honest reading is that attention from a structured program drives much of the benefit parents see.
That does not mean the gains parents observe are not real. It means HBOT itself is not the cause — the same gains appeared in sham. Cheaper options that provide the same structured attention may serve children equally well.
For deeper context on the marketing-vs-evidence split, see our evidence-vs-marketing breakdown of the leading HBOT chain and our analysis of institutional silence on HBOT.
What CP guidelines actually say
The American Academy of Pediatrics does not recommend HBOT for CP. The position has stood since the Collet trial.
The American Academy of Neurology CP practice guidelines do not include HBOT. CanChild and other CP research centers also do not recommend HBOT.
UHMS does not list CP on its 14 approved indications. The UHMS HBO indications page, 2024 is the source of truth.
Major academic pediatric centers do not offer HBOT for CP. Their wound care and dive medicine chambers run for the approved uses only.
Cost versus evidence
A 40-session course at a wellness clinic runs $6,000 to $15,000. Some centers run programs of 60-80 sessions, which run higher.
Parents face this cost without insurance support. HSA and FSA accounts may or may not accept the claim, depending on plan rules.
That price stacks against the cleanest negative RCT in HBOT history. The math poses a hard question — would $10,000 spent on extra physical therapy, adaptive equipment, or family respite serve the child more?
The framing is not that no parent should try this. The framing is that the evidence base is clear, and the same gains parents see may come from any structured attention.
What to ask your pediatric neurologist
Parents weighing HBOT for CP can ask a few key questions. Each cuts through clinic marketing.
What did the Collet 2001 Lancet trial show — the answer is "no benefit over room-air sham." What does the American Academy of Pediatrics say — the answer is "not recommended." Could the same money fund extra physical or occupational therapy — almost always yes.
For chamber-type details, see our hard-shell vs soft-shell chamber explainer. The Collet trial used hard-shell chambers from makers such as Sechrist Industries and Perry Baromedical, not the soft 1.3 ATA chambers from OxyHealth or Summit to Sea that many CP wellness clinics use. The room-air arm at 1.3 ATA in the Collet trial closely matches what soft-shell clinics deliver.
Distinguishing from FDA-approved uses
CP sits very differently from approved HBOT uses. The approved list — carbon monoxide poisoning, dive injury, stubborn bone infection, diabetic foot wounds, and ten more — all have decades of backing data and multi-center trials.
Our diabetic foot ulcer evidence atlas and carbon monoxide poisoning evidence atlas show what real FDA-approved HBOT evidence looks like — multiple independent trials, settled mechanism, insurance coverage.
CP has the opposite pattern. The cleanest sham-controlled trial in HBOT history was negative, and no specialty body endorses HBOT for CP. The honest call is not "investigational" — the honest call is "tested in the cleanest design and failed."
Frequently asked questions
Is HBOT FDA-approved for cerebral palsy?
No. The FDA recognizes 14 conditions for HBOT and CP is not among them. The UHMS approved indications list, current 2024, also does not include CP.
What did the Collet 2001 Lancet trial actually show?
The trial enrolled 111 children with CP. The active arm received 40 HBOT sessions at 1.75 ATA. The sham arm received 40 sessions of room air at 1.3 ATA. Both arms improved similarly. HBOT did not beat sham on any outcome.
Why do some parents report gains?
The Collet trial sham arm also reported gains. The most likely explanation is that any structured program with attention from caring providers produces observable improvement. HBOT specifically does not appear to be the cause.
Will Medicare or insurance cover this?
Generally no. Medicare and most commercial plans cover HBOT only for the 14 approved indications. CP is out-of-pocket at almost all clinics offering this protocol.
What does the American Academy of Pediatrics say?
The American Academy of Pediatrics does not recommend HBOT for CP. The American Academy of Neurology CP guidelines also do not include HBOT.
Sources
- Collet and colleagues Lancet 2001, PMID 11558483
- Lacey Annals of Neurology 2012, PMID 23071074
- Hardy follow-up cognitive analysis 2002, PMID 12463308
- McDonagh systematic review 2007, PMID 18039243
- AHRQ Evidence Report on HBOT for Brain Injury, 2003
- PLoS ONE systematic review on CP HBOT, 2022
- Long-term gait and balance RCT 2023, PMID 36832523
- CanChild HBOT position resource
- UHMS HBO Indications List, 2024
Medical disclaimer
This page is medical journalism and not medical advice. HBOT for cerebral palsy is an investigational off-label use without FDA approval. The largest sham-controlled randomized trial showed no benefit over sham. Standard CP care including physical, occupational, and speech therapy remains the guideline-recommended path. Talk to your child's pediatric neurologist before pursuing any out-of-pocket HBOT protocol. This page does not diagnose, treat, or substitute for professional medical care.